What is the NOAEL for Prop-2-en-1-yl heptanoate?
Prop-2-en-1-yl heptanoate has 32 NOAEL studies in the database. The lowest reported value is 0.15 mg/kg via oral in Human. Source: ToxValDB_WHO_JECFA_ADI.
Also known as: Heptanoic acid, 2-propenyl ester, Allyl heptanoate, Heptanoic acid, 2-propen-1-yl ester, Allyl enanthate, Allyl heptoate (+7 more)
CAS 142-19-8
Prop-2-en-1-yl heptanoate (CAS 142-19-8) is a chemical substance. Key regulatory status: REACH registered, 10 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, ECHA REACH.
Prop-2-en-1-yl heptanoate is classified GHS Danger (H301, H302, H312, H311, H315, H319, H373, H400) in the chemicals database but is restricted in EU cosmetics.
CAS, identifiers, formula, and alternate names for the matched substance record.
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| air; detected; emissions; Europe; Vehicle - car interior | Danish Environmental Protection Agency | Danish EPA |
| air; detected; emissions; Europe; Vehicle - car interior | Danish Environmental Protection Agency | Danish EPA |
| detected; Europe; Vehicle - car interior | Danish Environmental Protection Agency | Danish EPA |
| air; detected; emissions; Personal care | Elsevier | CPCat |
| air; Cleaning products and household care - air freshener; detected; emissions | Elsevier | CPCat |
| IFRA Transparency | IFRA | IFRA |
| Europe | European Commission | Fl@vis |
| food_additive; Substances Added to Food (formerly EAFUS) (2/2019) | FDA | United States Food and Drug Administration (FDA) |
| consumer_product | P&G | Proctor & Gamble |
| Europe; Personal care; restricted | European Commission | CosIng |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| <=0.15 | mg/kg | ADI | oral | Human | ToxValDB_WHO_JECFA_ADI |
| =2.97 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB_GESTIS_DNEL |
| AU4CYG9V68 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| AU4CYG9V68 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| AU4CYG9V68 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| AU4CYG9V68 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| - | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 1350 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| 2592 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| 25 | mg/kg bw/day | LOAEL | oral | dog | COSMOS_DB |
| 49.5999984741 | mg/kg bw/day | LOAEL | oral | rat | COSMOS_DB |
| 100 | mg/kg bw/day | LOAEL | oral | rat | COSMOS_DB |
| 5 | mg/kg bw/day | NOAEL | oral | rat | COSMOS_DB |
| 25 | mg/kg bw/day | NOAEL | oral | dog | COSMOS_DB |
| 30 | mg/kg bw/day | NOAEL | oral | rat | COSMOS_DB |
| 49.6 | mg/kg bw/day | NOAEL | oral | rat | COSMOS_DB |
| 75 | mg/kg bw/day | NOAEL | oral | dog | COSMOS_DB |
| 100 | mg/kg bw/day | NOAEL | oral | rat | COSMOS_DB |
| 3 | unitless | Relative reliability score | Dermal | Human | NTP_ICE_skin_sensitization |
| 94.3 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 97.01 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 98.9 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 99.53 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 101.07 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 101.13 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 101.33 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 102.09 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 102.2 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 103.7 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 105.4 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 105.9 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
| 109.4 | % | Viability | Dermal | - | NTP_ICE_skin_irritation |
Showing 32 of 32 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | Allyl heptanoate | 205-527-1 | ECHA overview → |
Australian industrial chemicals inventory status and applicable conditions.
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
Same-CAS cannabis compliance and lab records where available.
1 cannabis record found in efsa substances.
View full cannabis profile →Prop-2-en-1-yl heptanoate has 32 NOAEL studies in the database. The lowest reported value is 0.15 mg/kg via oral in Human. Source: ToxValDB_WHO_JECFA_ADI.
Prop-2-en-1-yl heptanoate appears on 9 regulatory/inventory lists including air; detected; emissions; Europe; Vehicle - car interior, detected; Europe; Vehicle - car interior, air; detected; emissions; Personal care, and 6 more. Source: EPA CPDat.
Yes, Prop-2-en-1-yl heptanoate is also indexed as a cosmetic ingredient under the name Allyl Heptanoate. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed, cannabis regulatory/lab databases. All data traces to primary regulatory sources and is updated from official government databases.
Prop-2-en-1-yl heptanoate is classified GHS Danger (H301, H302, H312, H311, H315, H319, H373, H400) in the chemicals database but is restricted in EU cosmetics.
Prop-2-en-1-yl heptanoate also appears in cosmetics, pharmaceutical, cannabis databases.